SPOTLIGHT -
Tax Trends from the Recession
Since the recession began in 2008, states have been struggling to balance their budgets, which often lead to tax increases.
Is Arena's Run Legit or Sure to Burst?
In the run up to next week's FDA decision on Arena Pharmaceuticals' weight-loss drug, investors have been sending the biotech's stock up.
Medicaid Audits Cost Far More than Discovered Fraud
After five years of audits to discover Medicaid fraud, $102 million were spent to find only $20 million in overpayments.
The Worry Over Regeneron is Unnecessary
Regeneron hasn't regained its footing since a rival eye drug combo worked in a trial.
Health Satisfaction in Emerging Economies Varies
Of the major emerging markets, only China and India have shown an increase over the past few years with the satisfaction of personal health. Russians are the least satisfied.
Scammed! Avoid Trouble on Vacation
A vacation can turn into sour very quickly if you discover you've become the victim of identity theft or a scam.
Gender Accounts for a $12,000 Salary Boost
A female physician researcher might find the idea of a $12,194 raise enticing, and she would only have to do one thing: swap genders.
Feeling the Pressure of the Student Loan Debt Bomb
The student loan debt bomb is understandably worrisome, but medical students have less to be concerned about.
Eli Lilly is Serious Competition in Diabetes Market
Eli Lilly & Co. is taking a shot at Sanofi with a new drug that matches Sanofi's Lantus at controlling blood sugar, but also helps patients lose weight.
Employed More Healthy; Unemployed Least
Americans working full time or part time had healthier habits than people who were unemployed. And the healthiest group of all was those people not in the workforce.
Docs Grade ACA Poorly; Better to Start Over on Health Reform
The Supreme Court will rule on the Affordable Care Act this month, but physicians grade the law so poorly, they think it should be scrapped and that Congress should start over.
Truvada Should Gain Approval, Benefitting Investors
In three months, the FDA will rule whether or not to approve Gilead Sciences' Truvada for HIV prevention, giving the company a huge advantage in a market it is already a leader in.
U.S. Docs Paid Less Than Counterparts in Other Countries
Despite the fact that U.S. health costs are among the highest in the world, its physicians are among the lowest paid of the major western nations (relatively speaking).
Amgen is Still Strong Despite Trial Failure
A late-stage trial of Amgen's drug Sensipar failed to meet the trial goal causing shares to fall, but only a little.
Top Ways to Save Money on Your Summer Road Trip
Summer is the ideal time for road trips. Whether you're just driving to the beach or trekking across the country, here are some money-saving tips.
Spectrum Pharma's Long-Term Potential
The strong set of drugs in Spectrum Pharmaceuticals' pipeline could mean that the company has some long-term potential for investors.
The Drugs Most Reported for Risks
Anticoagulants lead in the most number of reports for serious adverse events. In 2011 there was an increase of 9.4% in reported cases.
Workers Pushing Back Retirement Until 80?
According to the CEO of AIG, because of longer life expectancies, retirement age might be pushed back to 70 or 80.
Roche's Stock Takes Off
Roche has so impressed since ASCO with its various drug results - including its "smart bomb" breast cancer drug trastuzumab emtansine (T-DMI) - that the company's stock (RHHBY) shot up on the OTC Markets.
Key Factors in Defining Happiness
If you miss out on happiness in your 30s you could have another chance in your 60s, according to an AARP survey.
The Daily Stipends of On-Call Physicians
The most common form of compensation for on-call physicians is a daily stipend, and pay varies depending on specialty, location and group type.
Targacept CEO Steps Down After Series of Setbacks
After pipeline disappointments a corporate shake up might be just what Targacept needs as it moves forward with its remaining drugs.
After Volatile Ride Ampio Positions for Rebound
Although Ampio has had a volatile few months, with three strong drugs in the pipeline, the company is positioning itself for a rebound.
Alternative Investments Still Growing, But Slower
While alternative investments have continued to gain assets, excitement for them has diminished, which lead to slower growth in 2011.
ASCO '12 Standouts: Bristol Wows, J&J Hits Dendreon Hard
The markets opened on Monday with a host of new data from ASCO, including impressive news from Bristol and bad news for Dendreon.
New Cancer Cases to Increase 75% by 2030
By 2030 the number of people with cancer worldwide could increase by more than 75%.
Bids Could Push Amylin Up Higher
The roller coaster isn't over for the diabetes drug maker's stock, which first shot up in March over news that Bristol had placed a bid. But is the stock now overweight?
Health Spending Stays Sluggish; Particularly for Physician Services
Despite the expectation that health care spending growth would increase in 2012, it has not. In fact, it's also expected to remain slow in 2013.
Failed Drug Study Crushes Chelsea's Stock
After a failed midstage trial for a rheumatoid arthritis drug, Chelsea Therapeutics announced it ended studies on the drug causing the company's stock to plummet 33%.
Abbott Labs Gears Up for Company Split
Abbott Laboratories, which has a strong track record for dividend yield growth, is on the edge of something very big as it prepares to split the company into two.